gocanoeing
本站元老
- 注册
- 2006-11-21
- 消息
- 14,916
- 荣誉分数
- 2,104
- 声望点数
- 373
BEIJING -- China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.
The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.
It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment.
...
Pfizer in December said final trial results showed its treatment reduced the chance of hospitalization or death by 89% in COVID-19 patients at risk of severe illness given the treatment within three days of the onset of symptoms, and by 88% when given within five days of onset.
The United States is paying around US$530 for each course of Paxlovid and $700 for each course of rival COVID-19 pill molnupiravir developed by Merck & Co.
...
www.ctvnews.ca
The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.
It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment.
...
Pfizer in December said final trial results showed its treatment reduced the chance of hospitalization or death by 89% in COVID-19 patients at risk of severe illness given the treatment within three days of the onset of symptoms, and by 88% when given within five days of onset.
The United States is paying around US$530 for each course of Paxlovid and $700 for each course of rival COVID-19 pill molnupiravir developed by Merck & Co.
...
China approves use of Pfizer's COVID drug Paxlovid
China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.
